Supplementary Tables 2-8, 13 and 14 from Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines

This file contains Supplementary Tables 2-8, 13 and 14: Supplementary Table 2: Cell line doubling times estimated from growth curves of confluence measurements. Supplementary Table 3: Normalized dose response data for each of the seven kinase inhibitors. Supplementary Table 4: Absolute IC50 values estimated from the dose response data. Supplementary Table 5: Normalized and log-transformed read counts obtained from RNA sequencing. Supplementary Table 6: Mutations called from the DNA sequencing data. Supplementary Table 7: Copy number estimates obtained from the off-target DNA sequencing reads using CopywriteR. Supplementary Table 8: Protein and phosphorylation levels obtained from the RPPA assay. Supplementary Table 13: Comparison of mutation frequencies in the cell line panel with mutation frequencies observed for breast cancer in The Cancer Genome Atlas. Supplementary Table 14: Differential expression analysis of RPPA and RNAseq data between sensitive and resistant cell lines for each of the kinase inhibitors.